CN115317668A - Long-acting particle type I collagen implant - Google Patents
Long-acting particle type I collagen implant Download PDFInfo
- Publication number
- CN115317668A CN115317668A CN202211000723.2A CN202211000723A CN115317668A CN 115317668 A CN115317668 A CN 115317668A CN 202211000723 A CN202211000723 A CN 202211000723A CN 115317668 A CN115317668 A CN 115317668A
- Authority
- CN
- China
- Prior art keywords
- collagen
- particles
- type
- aqueous solution
- tyrosinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012422 Collagen Type I Human genes 0.000 title claims abstract description 42
- 108010022452 Collagen Type I Proteins 0.000 title claims abstract description 42
- 239000000501 collagen implant Substances 0.000 title claims abstract description 13
- 239000002245 particle Substances 0.000 title claims description 95
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 28
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000011859 microparticle Substances 0.000 claims abstract description 15
- 230000035515 penetration Effects 0.000 claims abstract description 10
- 229940096422 collagen type i Drugs 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims description 55
- 108010035532 Collagen Proteins 0.000 claims description 55
- 229920001436 collagen Polymers 0.000 claims description 55
- 239000012071 phase Substances 0.000 claims description 44
- 239000007864 aqueous solution Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 238000001914 filtration Methods 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 16
- 150000005846 sugar alcohols Chemical class 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 239000007762 w/o emulsion Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- 239000013557 residual solvent Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007943 implant Substances 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 43
- 230000015556 catabolic process Effects 0.000 description 18
- 238000006731 degradation reaction Methods 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 17
- 230000014759 maintenance of location Effects 0.000 description 15
- 239000003431 cross linking reagent Substances 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 11
- 238000003756 stirring Methods 0.000 description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 238000009777 vacuum freeze-drying Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000005923 long-lasting effect Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- -1 oleic acid glucose ester Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MIHINWMALJZIBX-UHFFFAOYSA-N cyclohexa-2,4-dien-1-ol Chemical compound OC1CC=CC=C1 MIHINWMALJZIBX-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010999 medical injection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FGPPDYNPZTUNIU-UHFFFAOYSA-N pentyl pentanoate Chemical compound CCCCCOC(=O)CCCC FGPPDYNPZTUNIU-UHFFFAOYSA-N 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a microparticle type I collagen implant with improved performance and a preparation method thereof. The collagen implant comprises: collagen type i microparticles crosslinked using tyrosinase. The implant has the advantages of long acting, long effective period (small fluctuation) and good needle penetration.
Description
Technical Field
The invention relates to an injection implant. In particular to a long-acting particle type I collagen implant with excellent performance.
Technical Field
Type I collagen is the most abundant collagen in the human body. It forms large eosinophilic fibers, called collagen fibers. It is present in scar tissue, the healing of the tissue in the final product by repair, and the organic part of the bone of the tendons, ligaments, myofibrils of the intima, the dermis, dentin and organ capsules.
Type I collagen plays the least role in inflammation and antigenic responses and has been approved by food and drug administration in china, the united states, for many types of medical applications, including wound dressings and artificial skin.
However, the major disadvantages of the type I collagen include short in vivo residence time.
Although, some long-acting collagen technologies exist, such as:
CN 101648989 (long-acting collagen and its manufacturing method): the invention discloses a long-acting collagen and a preparation method thereof, which comprises the steps of scraping redundant tissues, removing grease, swelling, digesting, centrifugally separating, salting out, collecting lower-layer precipitates, freeze-drying to obtain collagen, mixing the collagen with gamma-polyglutamic acid (gamma-PGA), simultaneously adding a glutaraldehyde solution, uniformly stirring, carrying out first crosslinking, repeatedly adding the glutaraldehyde solution, uniformly stirring, and carrying out second crosslinking to obtain the long-acting collagen, wherein the defects that the conventional collagen has too short retention time, needs to be supplemented frequently, and high-concentration glutaraldehyde is remained, so that the biological toxicity can harm the health of a human body and the like can be overcome;
CN102924731a (a triple cross-linked collagen and method of manufacture and use): a method for producing triple cross-linked collagen, comprising: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a re-cross-linked collagen; mixing the double cross-linked collagen with a second cross-linking agent to form double cross-linked collagen; and mixing the double cross-linked collagen with a third cross-linking agent to form triple cross-linked collagen. Wherein the first cross-linking agent, the second cross-linking agent, and the third cross-linking agent are each selected from the group consisting of: aldehyde cross-linking agent, imine cross-linking agent and epoxide cross-linking agent, wherein the first cross-linking agent is different from the second cross-linking agent, and the third cross-linking agent is different from the first cross-linking agent and the second cross-linking agent;
however, although the above-mentioned techniques employ a chemical modification method, although the effect is remarkable, there is a risk of chemical reagent remaining and harmful substances being formed during the modification, and there are also disadvantages that the reaction conditions are not mild, by-products are generated, the specificity is poor, the catalytic efficiency and yield are low, and collagen is lost during the process.
More importantly, the collagen is crosslinked throughout the homogeneous phase, or is crosslinked into a large particle, not a very small particle, not a substantially uniform particle, but a smaller particle when used, and thus, the apparent therapeutic effect is not consistent, e.g., the duration of the therapeutic effect is not long enough.
In addition, the preparation is basically gel, and the high viscosity of the water dispersion system causes inconvenience in production and use, such as inaccurate dosage split charging and poor needle penetration during injection.
Therefore, there is a need for a type I collagen implant that has the advantages of long duration, consistent duration of action (less fluctuation), and good penetration.
Disclosure of Invention
The invention aims to provide a particle type I collagen implant with improved performance, long acting, consistent and long effective period (small fluctuation) and good needle penetration and a preparation method thereof.
The inventor finds that the tyrosinase modifies the common type I collagen into the particle cross-linked collagen with basically uniform size, so that the action time of the collagen in the body can be prolonged, the effective period is consistent and long (the fluctuation is small), the viscosity of a water dispersion system is reduced, and a plurality of problems caused in production and use are solved, such as accurate subpackage dosage and better needle penetration during injection; in addition, the method can reduce the mixing of harmful substances, lead the reaction condition to be mild, reduce the loss of collagen in the process, improve the specificity, avoid generating byproducts, improve the catalytic efficiency, improve the yield and the like.
Tyrosinase has a unique dual catalytic function, and can catalyze the oxidation of monophenol to ortho-diphenol and further oxidize diphenol to ortho-benzoquinone. Throughout the catalytic process, oxygen molecules act as electron acceptors, are reduced to water rather than forming hydrogen peroxide, and 1 mol/L of oxygen molecules are required to oxidize 1 mol/L of monohydric phenol, while 0.5 mol/L of oxygen molecules are required to oxidize 1 mol/L of dihydric phenol. The final products released in these 2 catalytic processes are all quinones, which are precursors for melanin. Thus, tyrosinase can oxidize tyrosine in the side chains of proteins to quinones, thereby further crosslinking with lysine, tyrosine and cysteine residues present in proteins.
Based on this, the present invention has been completed.
The invention relates to a (performance-improved) long-acting, long-lasting (fluctuation is small), fine-particle type I collagen implant with good needle penetration, which comprises: collagen type i microparticles crosslinked using tyrosinase.
The invention relates to a preparation method of a microparticle type I collagen implant with long effect (improved performance), consistent and long effective period (small fluctuation) and good needle penetration, which comprises the following steps:
(1) Preparing a solution, namely an oil phase, which is not higher than 4 ℃ and comprises a surfactant and a volatile organic solvent which is not completely dissolved in water;
(2) Preparing an aqueous solution containing type I collagen, tyrosinase and sugar alcohol at a temperature of not higher than 4 ℃, namely an aqueous phase;
(3) Mixing the aqueous solution with the solution of the organic solvent within 30 minutes after the preparation of the aqueous solution is completed, and allowing them to form a water-in-oil emulsion, and keeping the temperature at 4 ℃ to-4 ℃ for more than 24 hours, preferably within 48 hours, to substantially crosslink the collagen;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain microparticles, washing the microparticles by using 10-40% ethanol water solution, and removing the residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme and the like;
(5) And removing residual solvent in the particles by a low-temperature freezing method.
Detailed Description
The particle size of the particles in the above particulate collagen implant is preferably between 5 μm and 25 μm, more preferably between 10 μm and 25 μm or between 5 μm and 15 μm.
Such sugar alcohols include, but are not limited to, sorbitol, mannitol, erythritol, maltitol, lactitol, xylitol, and combinations thereof. The sugar alcohol is used for protecting the activity of type I collagen and tyrosinase.
Preferably, the mass concentration of the above aqueous solution, i.e. type I collagen in the aqueous phase, is 0.1% to 10%, more preferably 0.5% to 5%; preferably, the ratio of the amount of tyrosinase to the amount of collagen type I is 1-10U/g, preferably 4-8U/g, more preferably 5-6U/g.
The organic solvent includes, but is not limited to, esters of C1-C6 acids and C1-C6 alcohols, such as ethyl acetate, methyl acetate, ethyl propionate, butyl acetate, amyl valerate, isoamyl isovalerate, etc.; ethers formed by C1-C6 alcohols and C1-C6 alcohols, such as diethyl ether, methyl ethyl ether; C3-C6 ketones, such as acetone.
Such surfactants include, but are not limited to, lipophilic surfactants, particularly those having an HLB value of 3 to 8, such as span surfactants, e.g., span20, 40, 60 or 80, sugar ester surfactants, e.g., glucose esters of C12 to C18 acids; propylene glycol C12-C18 acid esters; glycerol (glycerin) C12-C18 acid; to co-combine them.
The lipophilic surfactant may be used in combination with 0.1-5 wt% of hydrophilic surfactant, such as TWEEN 80.
Tyrosinase should be added to the aqueous phase before the water-in-oil emulsion is formed, and should not be added to the oil phase before or after the water-in-oil emulsion is formed, otherwise the type I collagen implant performance is degraded or disappears.
The volume ratio of the oil phase to the aqueous phase is 2.5 to 10, preferably 3 to 6.
After the preparation of the aqueous solution, the aqueous solution and the oily solution are mixed within 30 minutes, preferably within 10 minutes, and most preferably within 5 minutes.
Preferably, in the process of filtering the emulsion to obtain particles, filtering out particles with the particle size of more than 25 μm and less than 0.5 μm, and keeping the particles with the particle size of between 0.5 μm and 25 μm; more preferably, filtering out particles with a size greater than 25 μm and less than 5 μm, and retaining particles with a size between 5 μm and 25 μm; most preferably, particles having a size greater than 25 μm and less than 10 μm are leached or particles having a size greater than 15 μm and less than 5 μm are leached, and particles having a size between 10 μm and 25 μm are retained or particles having a size between 5 μm and 15 μm are retained.
The low-temperature freezing method includes freeze drying and spray freeze drying.
The process of the invention adopts an enzyme method to crosslink collagen, and has great advantages compared with a chemical crosslinking process and a physical crosslinking process:
mild reaction conditions, no by-product, high specificity, high catalytic efficiency and yield.
In addition, the mild reaction conditions of the enzyme reduce the loss of collagen during processing.
Examples
The following non-alternative example, a method of preparing an implant, further describes preferred embodiments within the scope of the present invention. Many variations of these embodiments are possible within the scope of the invention.
Example 1
(1) Preparation temperature 4 ℃ containing 3% of surfactant: SPAN 80 ethyl acetate solution to obtain oil phase;
(2) Preparing an aqueous solution containing 5% of type I collagen, 5% of sorbitol and tyrosinase at the temperature of 4 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 5U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 10 to 30 minutes after the preparation of the aqueous solution is completed, and intensively stirring for 30 minutes to form water-in-oil emulsion, keeping the temperature not higher than 4 ℃ to 0 ℃ for 48 hours to basically crosslink the collagen, wherein the volume ratio of the oil phase to the water phase is 5;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle diameter of more than 25 μm and less than 0.5 μm, retaining particles with particle diameter of 0.5 μm and 25 μm, washing the particles with 15% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, and the enzyme;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent from the particles.
15 batches were made in the same manner.
Example 2
(1) Preparation temperature 0 ℃ of 5% surfactant: the oleic acid glucose ester is dissolved in ethyl ether to obtain an oil phase;
(2) Preparing an aqueous solution containing 3% of type I collagen, 8% of mannitol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 7U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 5 to 10 minutes after the preparation of the aqueous solution is completed, and stirring strongly for 60 minutes to form water-in-oil emulsion, keeping the temperature at 0 to-4 ℃ for 24 hours to basically crosslink the collagen, wherein the volume ratio of the oil phase to the water phase is 3;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle diameter of more than 5 μm and less than 0.5 μm, retaining particles with particle diameter of 0.5 μm and 5 μm, washing the particles with 30% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, and the enzyme;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent from the particles.
15 batches were made in the same manner.
Example 3
(1) Preparation temperature 0 ℃ of a surfactant containing 6%: acetone solution of C12 acid (lauric acid) glyceride to obtain oil phase;
(2) Preparing an aqueous solution containing 10% of type I collagen, 3% of erythritol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 10U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 1 to 5 minutes after the preparation of the aqueous solution is completed, and intensively stirring for 40 minutes to form water-in-oil emulsion, keeping the temperature at 0 ℃ to-4 ℃ for 48 hours to basically crosslink the collagen, wherein the volume ratio of the oil phase to the water phase is 8;
(4) Filtering the emulsion to obtain particles: filtering with filter membrane to remove particles with particle size of more than 25 μm and less than 5 μm, retaining particles with particle size between 5 μm and 25 μm, washing the particles with 20% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent from the particles.
The same method is used for manufacturing 15 batches.
Example 4
(1) Preparation temperature 0 ℃ of 5% surfactant: propylene glycol stearate (C18) and 0.1% solution of TWEEN 80 in isoamyl isovalerate to form an oil phase;
(2) Preparing an aqueous solution containing 2% of type I collagen, 6% of maltitol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 5U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 5 to 25 minutes after the preparation of the aqueous solution is completed, and stirring strongly for 60 minutes to form water-in-oil emulsion, keeping the temperature at 0 to-4 ℃ for 48 hours to make collagen basically cross-linked, wherein the volume ratio of the oil phase to the water phase is 6;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle size of more than 15 μm and less than 5 μm, retaining particles with particle size between 5 μm and 15 μm, washing the particles with 15% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent in the microparticles.
15 batches were made in the same manner.
Example 5
(1) Preparation temperature 0 ℃ of 3% surfactant: SPAN20 butyl acetate solution to obtain oil phase;
(2) Preparing an aqueous solution containing 5% of type I collagen, 10% of xylitol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 6U/g, and obtaining a water phase;
(3) Mixing the aqueous solution and the oil phase within 5 to 25 minutes after the preparation of the aqueous solution is finished, forcibly stirring the aqueous solution and the oil phase for 20 minutes to form water-in-oil emulsion, keeping the temperature between 0 ℃ and-4 ℃ for 48 hours to basically crosslink the collagen, wherein the volume ratio of the oil phase to the water phase is 7.5;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle size of more than 25 μm and less than 5 μm, retaining particles with particle size between 5 μm and 25 μm, washing the particles with 25% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent from the particles.
15 batches were made in the same manner.
Example 6
(1) Preparation temperature 0 ℃ of a surfactant containing 6%: sucrose palmitate (C16 acid) and 0.1% TWEEN 80 methyl acetate to obtain oil phase;
(2) Preparing an aqueous solution containing 6% of type I collagen, 5% of lactitol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 10U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 5 to 25 minutes after the preparation of the aqueous solution is completed, and intensively stirring for 50 minutes to form water-in-oil emulsion, keeping the temperature at 0 ℃ to-4 ℃ for 48 hours to basically crosslink the collagen, wherein the volume ratio of the oil phase to the water phase is 8;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle size of more than 25 μm and less than 5 μm, retaining particles with particle size between 5 μm and 25 μm, washing the particles with 35% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent in the microparticles.
15 batches were made in the same manner.
Example 7
(1) Preparation temperature 0 ℃ of 5% surfactant: the oleic acid glucose ester is dissolved in ethyl ether to obtain an oil phase;
(2) Preparing an aqueous solution containing 3% of type I collagen, 8% of mannitol and tyrosinase at the temperature of 1 ℃, wherein the ratio of the amount of the tyrosinase to the type I collagen is 7U/g, and obtaining a water phase;
(3) Mixing the aqueous solution with the oil phase within 5 to 10 minutes after the preparation of the aqueous solution is completed, and stirring strongly for 60 minutes to form water-in-oil emulsion, keeping the temperature at 0 ℃ to-4 ℃ for 48 hours to make collagen basically cross-linked, wherein the volume ratio of the oil phase to the water phase is 3;
(4) Filtering the emulsion after the collagen is basically crosslinked to obtain particles: filtering with filter membrane to remove particles with particle size of more than 25 μm and less than 10 μm, retaining particles with particle size between 10 μm and 25 μm, washing the particles with 30% ethanol water solution, and removing residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And freeze-drying in a vacuum freeze-drying machine at-60- -80 deg.C for 48 hr to remove residual solvent from the particles.
15 batches were made in the same manner.
Comparative examples 1 to 7-1
The same applies to the respective corresponding examples, except that no particles having a particle size greater than 25 μm or 5 μm or 10 μm or 15 μm or 20 μm (which is the same as the respective corresponding examples) and less than 0.5 μm or 5 μm or 10 μm or 15 μm (which is the same as the respective corresponding examples) are filtered out.
Comparative examples 1 to 7-2
The same applies to the respective corresponding examples, except that no particles having a particle size of more than 25 μm or 5 μm or 10 μm or 15 μm or 20 μm (which is the same as the respective corresponding examples) are filtered out.
Comparative examples 1 to 7 to 3
The examples were identical with the corresponding examples except that fine particles having a particle diameter of less than 0.5 μm or 5 μm or 10 μm or 15 μm (which is the same as the corresponding examples) were not filtered out.
Comparative examples 1 to 7 to 4
The same applies to the respective corresponding examples, except that tyrosinase was not added (directly) to the aqueous phase, but rather to the oil phase.
Comparative examples 1 to 7 to 5
The same applies to the respective corresponding examples, except that no surfactant is added, no particles having a particle size of more than 25 μm or 5 μm or 10 μm or 15 μm or 20 μm (the same value as in the respective corresponding examples) and less than 0.5 μm or 5 μm or 10 μm or 15 μm (the same value as in the respective corresponding examples) are leached.
Test example 1 through needle Performance test
The principle is as follows: the better the needle penetration performance, the less time it takes for the same amount of suspension to pass through the same needle under the same conditions.
The method comprises the following steps:
the same amount (8 mg) of collagen type I (8 mg, lyophilized preparation, hizibo Bio-pharmaceuticals Co., ltd.) as in the above examples, comparative examples and commercial products was added to the same amount (5 ml) of physiological saline for medical injection and reconstituted (reconstituted) in the same manner and for the same time (by the same shaking method), the same amount of suspension was filled in the same syringe (the needle was also changed, and the syringe was dried and reused after cleaning), the syringe was injected with the same constant pressure to discharge the suspension, and the time required was measured. And finally, respectively calculating the ratio of the time measured in the above embodiment and the time measured in the comparison example to the time measured in a commercial product, and measuring the needle passing performance of the above embodiment and the comparison example by using the ratio, wherein the smaller the ratio is, the stronger the needle passing performance is, and the larger the ratio is, the weaker the needle passing performance is.
The test results are shown in tables 1 to 7.
Test example 2
In vitro degradation time test
The above examples, comparative examples and commercial products of type I collagen (8 mg) were reconstituted in the same manner and for the same time into suspensions by adding the same amount (10 ml, concentration 0.08%) of medical injectable physiological saline (pH 7.0) to the same amount (8 mg, lyophilized preparation, shanxi brocade biomedical Co., ltd.) of type I collagen (8 mg). In the above suspensionAdding the same amount of collagenase (Bacillus cereus protease, purified and separated from Bacillus cereus) at a weight ratio of 4U/mg to the collagen, and sampling in a constant temperature and humidity environment at 37 deg.C and 70% relative humidity for 0hr, 1 hr, 3 hr, 5 hr, 7 hr, 9 hr, 11 hr, 13 hr, 15 hr, 17 hr, … … until the absorbance value A is substantially stable (fluctuation range is less than 2%), wherein the average value of the stability value A is expressed as A 0 。
After sampling, inactivating enzyme at 90 ℃ for 10min, cooling to room temperature, and centrifuging at 4000 r/min for 10min to obtain clear hydrolysate. And (2) adding 5mL of 15% (W/W) trichloroacetic acid (TCA) aqueous solution into 5mL of the hydrolysate sample solution, uniformly mixing, standing for 10min, centrifuging for 10min at 4 000r/min, diluting the supernatant to a solution with the concentration of 1-10 mg/mL, adding 4mL of biuret reagent into 1mL of the diluent, uniformly mixing, and standing for 30min. The absorbance value A was measured at a wavelength of 540 nm. The concentration of the polypeptide C (mg/mL) produced by degradation can be calculated according to a linear regression equation (see document 1: meat industry, 2011, (11), general No. 367, pp.21-24, liu Lili, yang Xieli, kinetic study of collagenase enzymolysis of bovine bone collagen).
The absorbance value A (or the concentration C of the polypeptide produced by degradation) reflects the amount of degraded collagen in the sample solution 0 -A (or C) 0 -C,C 0 Represents the average value A after the absorbance value A is substantially stabilized 0 The determined concentration of the polypeptide produced by degradation, i.e., the concentration of the polypeptide produced by complete degradation of collagen and the amount of collagen at the time of initiation of the reaction) reflects the amount of the collagen remaining in the sample solution, and it is known from the equation of mie that the protease degradation exhibits the first-order reaction characteristic at a lower concentration (see the above document 1), so ln (A) can be used 0 -A) (or ln (C) 0 -C)) is plotted against time T, and the degradation slope k is determined from said slope k and the formula T 0.99 Complete degradation of collagen (99% degradation or 1% residue), t = ln (C) was calculated for = ln100/k 0 '/ C')/k, t C'/ C 0 ' =0.01, wherein C 0 Respectively representing original collagenAmount of protein and amount of residual collagen) of the collagen composition 0.99 。
Finally, the time T for complete degradation of collagen measured in the above examples and comparative examples was calculated 0.99 Time T for complete degradation of collagen measured with commercially available products 0.99 The ratio, which is a measure of the relative in vivo retention properties of the above examples and controls, is larger, the greater the in vivo retention (longevity) property, and smaller, the weaker the in vivo retention (longevity) property. The smaller the ratio fluctuation is, the smaller the change of the retention (long-acting) performance of the collagen in the body is; the larger the ratio fluctuation, the larger the change in the retention (long-lasting) properties of collagen in vivo.
The test results are shown in tables 1 to 7.
TABLE 1
Example 1 | Comparative example 1-1 | Comparative examples 1 to 2 | Comparative examples 1 to 3 | Comparative examples 1 to 4 | Comparative examples 1 to 5 | |
Performance of needle | 0.26 | 0.49 | 0.56 | 0.25 | - | - |
Ratio of time to degradation | 4.6±37% | 5.8±62% | 7.1±75% | 3.4±51% | 1.2±26% | 9.5±83% |
TABLE 2
Example 2 | Comparative example 2-1 | Comparative example 2-2 | Comparative examples 2 to 3 | Comparative examples 2 to 4 | Comparative examples 2 to 5 | |
Performance of needle passing | 0.11 | 0.33 | 0.40 | 0.14 | - | - |
Ratio of degradation time | 2.3±22% | 3.5±47% | 4.9±56% | 1.7±36% | 1.0±18% | 7.2±68% |
TABLE 3
Example 3 | Comparative example 3-1 | Comparative example 3-2 | Comparative examples 3 to 3 | Comparative examples 3 to 4 | Comparative examples 3 to 5 | |
Performance of needle passing | 0.31 | 0.46 | 0.58 | 0.34 | - | - |
Ratio of time to degradation | 5.2±32% | 6.9±52% | 8.2±70% | 4.1±43% | 1.3±28% | 10.8±75% |
TABLE 4
Example 4 | Comparative example 4-1 | Comparative example 4-2 | Comparative examples 4 to 3 | Comparative examples 4 to 4 | Comparative examples 4 to 5 | |
Performance of needle | 0.22 | 0.41 | 0.48 | 0.24 | - | - |
Ratio of degradation time | 3.0±23% | 5.5±51% | 6.8±68% | 2.1±41% | 1.2±26% | 9.3±79% |
TABLE 5
Example 5 | Comparative example 5-1 | Comparative example 5-2 | Comparative examples 5 to 3 | Comparative examples 5 to 4 | Comparative examples 5 to 5 | |
Performance of needle passing | 0.33 | 0.51 | 0.63 | 0.31 | - | - |
Ratio of time to degradation | 5.6±31% | 7.6±55% | 9.4±71% | 4.1±47% | 1.4±27% | 11.6±84% |
TABLE 6
Example 6 | Comparative example 6-1 | Comparative example 6-2 | Comparative examples 6 to 3 | Comparative examples 6 to 4 | Comparative examples 6 to 5 | |
Performance of needle passing | 0.29 | 0.47 | 0.59 | 0.27 | - | - |
Ratio of time to degradation | 5.4±32% | 7.3±53% | 9.2±68% | 3.9±43% | 1.3±24% | 11.8±85% |
TABLE 7
Example 7 | Comparative example 7-1 | Comparative example 7-2 | Comparative example 7-3 | Comparative examples 7 to 4 | Comparative examples 7 to 5 | |
Performance of needle passing | 0.35 | 0.59 | 0.72 | 0.37 | - | - |
Ratio of time to degradation | 6.9±25% | 9.1±56% | 10.7±72% | 4.4±47% | 1.4±23% | 13.4±89% |
The results show that:
1) Examples have slower enzymatic hydrolysis rates, significantly longer in vivo retention (long-lasting) performance than commercial products;
2) The examples have better in vivo retention (long-lasting) performance than the control example without the addition of the surfactant, and the fluctuation of the in vivo retention (long-lasting) performance of the control example is extremely large;
3) The examples have better in vivo persistence (long-acting) properties than the control example in which tyrosinase was not (directly) added to the aqueous phase but to the oil phase, and the in vivo persistence (long-acting) properties of the control example were extremely weak;
4) Examples the control, which did not filter out larger and smaller particles, had better in vivo retention (longevity) performance, less variability, and had a large fluctuation in vivo retention (longevity) performance;
5) Examples the control example in which only smaller particles were filtered out, but larger particles were filtered out, had better in vivo retention (retention) performance, less fluctuation, and the control example in which the in vivo retention (retention) performance fluctuated more;
6) The control example which only filters larger particles but filters smaller particles has better in-vivo persistence (long-acting) performance, longer in-vivo persistence (long-acting) performance and smaller volatility, and the control example has shorter in-vivo persistence (long-acting) performance and larger volatility;
7) The embodiment has better needle passing performance than the commercial product, the comparison example which does not filter out larger and smaller particles and the comparison example which only filters out smaller particles without filtering out larger particles; the examples have substantially the same stylet performance as the control example in which smaller particles are not filtered but only larger particles are filtered.
Claims (11)
1. A preparation method of a long-acting microparticle type I collagen implant with small effect period fluctuation and good needle penetration performance comprises the following steps:
(1) Preparing a solution, namely an oil phase, which is not higher than 4 ℃ and comprises a surfactant and a volatile organic solvent which is not completely dissolved in water;
(2) Preparing an aqueous solution containing type I collagen, tyrosinase and sugar alcohol at a temperature of not higher than 4 ℃, namely an aqueous phase;
(3) Mixing the aqueous solution with the solution of the organic solvent within 30 minutes after the preparation of the aqueous solution is finished, forming the aqueous solution and the solution of the organic solvent into water-in-oil emulsion, and keeping the temperature between 4 ℃ below zero and 4 ℃ below zero for more than 24 hours to crosslink the collagen;
(4) Filtering the emulsion after the collagen crosslinking to obtain microparticles, filtering to remove microparticles with a particle size of more than 25 μm and less than 0.5 μm, retaining microparticles with a particle size of between 0.5 μm and 25 μm, washing the microparticles with 10-40% aqueous ethanol solution, and removing the residues of the surfactant, the organic solvent, the sugar alcohol, the enzyme, etc.;
(5) And removing residual solvent in the particles by a low-temperature freezing method.
2. Preparation process according to claim 1, characterized in that the sugar alcohol is selected from the group consisting of sorbitol, mannitol, erythritol, maltitol, lactitol, xylitol, and combinations thereof.
3. The method according to claim 1, characterized in that the concentration by mass of the type I collagen in the aqueous solution is 0.1% to 10%.
4. The method according to claim 1, characterized in that the ratio of the amount of tyrosinase to the amount of collagen type i is 1-10U/g.
5. The method of claim 1, wherein the organic solvent comprises an ester of a C1-C6 acid with a C1-C6 alcohol, an ether of a C1-C6 alcohol with a C1-C6 alcohol, a C3-C6 ketone, and combinations thereof.
6. The process according to claim 1, characterized in that the surfactant is selected from lipophilic surfactants having an HLB value of from 3 to 8.
7. The method according to claim 1, wherein the volume ratio of the oil phase to the aqueous phase is 2.5 to 10.
8. The process according to claim 1, characterized in that it comprises filtering off particles having a size greater than 25 μm and less than 5 μm and retaining particles having a size between 5 μm and 25 μm.
9. The process according to claim 1, characterized in that it comprises filtering the particles with a size greater than 25 μm and less than 10 μm and retaining the particles with a size between 10 μm and 25 μm.
10. The preparation method according to claim 1, characterized in that the low-temperature freezing method comprises a freeze-drying method or a spray-freeze-drying method.
11. A long-acting, low-fluctuation effective period, good needle penetration microparticle type I collagen implant, comprising: tyrosinase crosslinked type I collagen microparticles having a particle size of between 0.5 μm and 25 μm are used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211000723.2A CN115317668B (en) | 2022-08-19 | 2022-08-19 | Long-acting microparticle type I collagen implant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211000723.2A CN115317668B (en) | 2022-08-19 | 2022-08-19 | Long-acting microparticle type I collagen implant |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115317668A true CN115317668A (en) | 2022-11-11 |
CN115317668B CN115317668B (en) | 2023-12-29 |
Family
ID=83925368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211000723.2A Active CN115317668B (en) | 2022-08-19 | 2022-08-19 | Long-acting microparticle type I collagen implant |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115317668B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010287A1 (en) * | 1990-12-06 | 1992-06-25 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Method of producing collagen particles, and the use of such particles as substrates for active substances |
US20060222680A1 (en) * | 2005-03-31 | 2006-10-05 | Chunlin Yang | Method of preparing crosslinked collagen microspheres |
JP2009167136A (en) * | 2008-01-18 | 2009-07-30 | Hokkaido Univ | Sustained release microparticle, and method for producing sustained release microparticle |
US20130116188A1 (en) * | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Implantable hyaluronic acid/collagen compositions |
JP2014128686A (en) * | 2007-05-23 | 2014-07-10 | Allergan Inc | Cross-linked collagen and use of the same |
CN107213028A (en) * | 2017-05-26 | 2017-09-29 | 陕西慧康生物科技有限责任公司 | A kind of collagen implant and preparation method thereof |
WO2019216678A1 (en) * | 2018-05-10 | 2019-11-14 | 서울대학교산학협력단 | Cross-linking material having adhesive strength, prepared using burkholderia-derived tyrosinase, preparation method therefor, and application thereof |
CN110841108A (en) * | 2019-12-27 | 2020-02-28 | 南京思元医疗技术有限公司 | Preparation method of polylactic acid microparticles and injectable soft tissue filler |
JPWO2021187510A1 (en) * | 2020-03-17 | 2021-09-23 | ||
CN114085394A (en) * | 2021-12-16 | 2022-02-25 | 西安德诺海思医疗科技有限公司 | Recombinant collagen two-phase gel and preparation method and application thereof |
CN114470330A (en) * | 2021-12-30 | 2022-05-13 | 江苏江山聚源生物技术有限公司 | Recombinant collagen gel particles for tissue filling and preparation method thereof |
-
2022
- 2022-08-19 CN CN202211000723.2A patent/CN115317668B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010287A1 (en) * | 1990-12-06 | 1992-06-25 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Method of producing collagen particles, and the use of such particles as substrates for active substances |
EP0561821A1 (en) * | 1990-12-06 | 1993-09-29 | Lohmann Therapie Syst Lts | Method of producing collagen particles, and the use of such particles as substrates for active substances. |
US20060222680A1 (en) * | 2005-03-31 | 2006-10-05 | Chunlin Yang | Method of preparing crosslinked collagen microspheres |
JP2014128686A (en) * | 2007-05-23 | 2014-07-10 | Allergan Inc | Cross-linked collagen and use of the same |
JP2009167136A (en) * | 2008-01-18 | 2009-07-30 | Hokkaido Univ | Sustained release microparticle, and method for producing sustained release microparticle |
US20130116188A1 (en) * | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Implantable hyaluronic acid/collagen compositions |
CN107213028A (en) * | 2017-05-26 | 2017-09-29 | 陕西慧康生物科技有限责任公司 | A kind of collagen implant and preparation method thereof |
WO2019216678A1 (en) * | 2018-05-10 | 2019-11-14 | 서울대학교산학협력단 | Cross-linking material having adhesive strength, prepared using burkholderia-derived tyrosinase, preparation method therefor, and application thereof |
CN110841108A (en) * | 2019-12-27 | 2020-02-28 | 南京思元医疗技术有限公司 | Preparation method of polylactic acid microparticles and injectable soft tissue filler |
JPWO2021187510A1 (en) * | 2020-03-17 | 2021-09-23 | ||
CN114085394A (en) * | 2021-12-16 | 2022-02-25 | 西安德诺海思医疗科技有限公司 | Recombinant collagen two-phase gel and preparation method and application thereof |
CN114470330A (en) * | 2021-12-30 | 2022-05-13 | 江苏江山聚源生物技术有限公司 | Recombinant collagen gel particles for tissue filling and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
JUS, S等: "Cross-linking of collagen with laccases and tyrosinases", MATERIALS SCIENCE & ENGINEERING C, vol. 31, no. 5, pages 1068 - 1077, XP028210202, DOI: 10.1016/j.msec.2011.03.007 * |
Also Published As
Publication number | Publication date |
---|---|
CN115317668B (en) | 2023-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102034871B1 (en) | Dermal filler of polycaprolactone microspheres containing vitamin C and method for preparing the same | |
EP3335696B1 (en) | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract | |
RU2618329C2 (en) | Method of producing hydrogels | |
KR100880622B1 (en) | Composition and method for the repair and regeneration of cartilage and other tissues | |
Mahoney et al. | Current therapeutic strategies for adipose tissue defects/repair using engineered biomaterials and biomolecule formulations | |
NZ567216A (en) | Encapsulation system | |
FR2900575A1 (en) | BIOCOMPATIBLE CONTROLLED RELEASE GEL, PREPARATION METHOD AND USE THEREOF | |
Masuda et al. | Photocured, styrenated gelatin-based microspheres for de novo adipogenesis through corelease of basic fibroblast growth factor, insulin, and insulin-like growth factor I | |
CN101842084A (en) | Comprise microgranule of PCL and uses thereof | |
FR2991876A1 (en) | COMPOSITION, IN AQUEOUS MEDIUM, COMPRISING AT LEAST ONE HYALURONIC ACID AND AT LEAST ONE WATER-SOLUBLE SALT OF SUCROSE OCTASULFATE | |
CN115252898B (en) | Long-acting microparticle type I and type V collagen composite implant | |
FR3116534A1 (en) | Chitosan-based beads, preparation, compositions and applications | |
CN103785060B (en) | Fish skin collagen support loading epidermal growth factors and preparation method thereof | |
EP1587556A2 (en) | Ceramic-based injectable implants which are used to fill wrinkles, cutaneous depressions and scars, and preparation method thereof | |
CN115317668B (en) | Long-acting microparticle type I collagen implant | |
KR102431839B1 (en) | Composition for wound treatment or tissue regeneration comprising a mixture of poloxamer, hyaluronic acid, and extracellular matrix and use thereof | |
JP2012500118A (en) | Method for treating a composition comprising microparticles | |
CN114206405B (en) | Medical composition comprising adipose tissue-derived extracellular matrix and method for producing same | |
EP0621776B1 (en) | Injectable composition containing collagen microcapsules | |
CN115300614A (en) | Long-acting particle collagen implant | |
CN115350329A (en) | Long-acting particle type I and type III collagen composite implant | |
US20190054157A1 (en) | Composition and method of preparation of protease microparticulate slow release preparation | |
CN115350328A (en) | Long-acting particle III type collagen implant | |
CN115340597A (en) | Preparation method of long-acting implantation-level type II collagen | |
CH672887A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230921 Address after: Room 801, 8th Floor, Building 10, Courtyard 2, Kechuang 6th Street, Daxing District Economic and Technological Development Zone, Beijing 102211 Applicant after: Beijing Xihong Runmei Pharmaceutical Technology Co.,Ltd. Address before: 215626 Building 16, No. 27, Jinxing Road, Jinfeng Town, Zhangjiagang City, Suzhou, Jiangsu Province Applicant before: Jiangsu Dongfang Yanmei Biotechnology Development Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |